Press release
Roxadustat Market Overview, Key Trends, and Major Player Analysis
Roxadustat Market
Projected Value and Growth Potential of the Roxadustat Market
The roxadustat market is anticipated to experience robust growth, reaching a value of $9.56 billion by 2030. This represents a compound annual growth rate (CAGR) of 6.9% over the forecast period. The expansion is largely fueled by the increasing global prevalence of anemia, a growing patient base with chronic kidney disease (CKD), and a rising preference for oral therapies. Additionally, enhanced outpatient management of anemia and improved accessibility to innovative anemia drugs are contributing factors. Throughout the forecast period, notable trends include the wider adoption of oral anemia treatments, greater use of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) drugs, an intensified focus on anemia linked to CKD, a move away from injectable erythropoiesis-stimulating agents (ESAs), and the broader availability of anemia therapies.
Download a free sample of the roxadustat market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Leading Companies Shaping the Roxadustat Market Landscape
Several prominent companies hold influential positions in the roxadustat market. These include AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy's Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., Suzhou Biosyntech Co. Ltd., and Shanvr Life Sciences Pvt. Ltd.
Strategic Collaborations Within the Roxadustat Market
In February 2024, FibroGen Inc., a biopharmaceutical firm based in the United States, announced a strategic partnership with Astellas Pharma Inc. and AstraZeneca PLC. This collaboration aims to jointly develop and commercialize roxadustat for treating anemia associated with conditions such as CKD and myelodysplastic syndromes (MDS). Astellas Pharma is headquartered in Japan, while AstraZeneca PLC is a UK-based pharmaceutical company. Together, they bring extensive expertise in advancing roxadustat's therapeutic applications globally.
View the full roxadustat market report:
https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
How Real-World Evidence is Influencing Roxadustat Market Growth
An important trend in the roxadustat market is the increased focus on generating real-world evidence (RWE). This involves collecting clinical data outside of controlled clinical trials, reflecting actual patient outcomes in everyday healthcare settings. By sponsoring large-scale observational registry studies, companies aim to strengthen the understanding of roxadustat's long-term safety, effectiveness, and usage patterns. Real-world data is becoming essential for healthcare payers and regulatory bodies when making evaluation and reimbursement decisions.
Real-World Evidence Initiatives Enhancing Roxadustat's Market Position
For example, in May 2024, Astellas Pharma completed the launch of the WINE study via the WiNe Registry in Germany. This non-interventional cohort study captures key clinical outcomes, dosing information, and hemoglobin response in patients treated with EVRENZO (roxadustat). The findings help validate the drug's effectiveness in real-world CKD populations and support ongoing reimbursement and market adoption. Thus, RWE generation plays a significant role in propelling market growth.
Key Roxadustat Market Segments Driving Demand
This report breaks down the roxadustat market into several key segments:
1) By Type: 20mg and 50mg dosages
2) By Product Formulation: Oral Tablets
3) By Distribution Channel: Hospitals, Specialty Pharmacies, and Dialysis Centers
4) By End-User Application: Chronic Kidney Disease-Associated Anemia and Other Anemia Conditions
These segments help provide a detailed understanding of where demand is focused and how the market is structured across different uses and delivery channels.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Roxadustat Market Overview, Key Trends, and Major Player Analysis here
News-ID: 4501302 • Views: …
More Releases from The Business Research Company
Top Companies and Market Competition in the Sodium Hyaluronate-Based Products Se …
The sodium hyaluronate-based products market is gaining significant traction, driven by technological progress and expanding applications across health and beauty sectors. As consumer preferences evolve and demand rises for innovative, minimally invasive treatments, this market is set for notable growth in the coming years. Let's explore the current market size, key players, emerging trends, and segment breakdowns shaping this dynamic industry.
Forecasted Market Size and Growth Trajectory of Sodium Hyaluronate-Based Products…
Analysis of Segments and Major Growth Areas in the Single-Cell Omics Market
The single-cell omics sector is gaining remarkable traction as scientific advancements continue to push the boundaries of cellular analysis. This market is poised for substantial growth, driven by technological innovations and increasing applications across precision medicine and pharmaceutical research. Let's explore the market's future size, leading players, prevailing trends, and key segments shaping its development.
Projected Market Size and Growth Rate of the Single-Cell Omics Market
The single-cell omics market…
Overview of Segmentation, Market Dynamics, and Competitive Landscape in the Smal …
The small molecule targeted therapy market is on track for substantial growth as advances in personalized medicine and drug development strategies continue to evolve. This sector is becoming increasingly important due to its ability to deliver precise treatments that address specific molecular targets in various diseases. Let's explore the market's expected expansion, key players, emerging trends, and segment breakdown to understand its future trajectory.
Projected Market Size of the Small Molecule…
Key Players and Competitive Dynamics in the Short-Acting Insulin Market
The short-acting insulin market is on track for notable expansion as demand for effective diabetes management solutions continues to rise. Driven by increasing prevalence of type 2 diabetes and advancements in insulin delivery, this market is set to experience steady growth through the end of the decade. Let's explore the market's growth projections, key players, emerging trends, and the breakdown of its segments.
Projected Market Growth and Size of the Short-Acting…
More Releases for Roxadustat
Top Trends Transforming the Roxadustat Market Landscape in 2025: Roxadustat Reim …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Roxadustat Industry Market Size Be by 2025?
There has been a robust growth in the roxadustat market in the past few years. The market is predicted to expand from a size of $6.44 billion in 2024 to $6.86 billion in 2025, exhibiting a compound annual growth…
Roxadustat Market Size Projected To Reach 9.15 Billion By 2034 With A Cagr Of 7. …
"We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Is the Projected Growth of the Roxadustat Market?
Over the past few years, the Roxadustat market has exhibited robust growth. It is projected to rise from $6.44 billion in 2024 to $6.92 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. Factors such as regulatory green signals in…
Roxadustat Market Industry Analysis by Size, Share, Growth, Sourcing Strategy, S …
" As of 2024, the global Roxadustat market is valued at approximately $1.1 billion, driven by increasing demand for innovative therapies to treat anemia, particularly in patients with chronic kidney disease (CKD). The market is projected to grow to around $3.2 billion by 2034, reflecting a robust expansion fueled by an aging population, escalating CKD prevalence, and ongoing clinical research into Roxadustat's efficacy."
Exactitude Consultancy., Ltd. released a research report titled…
Roxadustat Market Industry Analysis by Size, Share, Growth, Sourcing Strategy, S …
" As of 2024, the global Roxadustat market is valued at approximately $1.1 billion, driven by increasing demand for innovative therapies to treat anemia, particularly in patients with chronic kidney disease (CKD). The market is projected to grow to around $3.2 billion by 2034, reflecting a robust expansion fueled by an aging population, escalating CKD prevalence, and ongoing clinical research into Roxadustat's efficacy."
Exactitude Consultancy., Ltd. released a research report titled…
In-Depth Analysis of the Roxadustat Market: Growth Opportunities, Key Trends, an …
What industry-specific factors are fueling the growth of the roxadustat market?
The growing number of individuals with chronic kidney disease (CKD) is expected to drive the growth of the Roxadustat market. CKD is a long-term condition in which the kidneys progressively lose their ability to function properly, potentially leading to kidney failure if untreated. The rising number of CKD patients globally is attributed to factors such as aging populations, increased rates…
Chemotherapy Induced Anemia Market Forecast 2032: FDA, EMA, PDMA Approvals, Clin …
Chemotherapy Induced Anemia companies are Astellas, FibroGen, AstraZeneca, Aileron Therapeutics, Zydus Cadila, Pfizer Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen Inc., Novartis AG, 3SBio Group, Bristol-Myers Squibb, FibroGen, and others.
(Albany, USA) DelveInsight's "Chemotherapy Induced Anemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chemotherapy Induced Anemia, historical and forecasted epidemiology as well as the Chemotherapy Induced Anemia market trends in the United States, EU5…
